Novartis AG

NOVN

CH0012005267

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (81.7%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal disorders, cancers, central nervous system disorders, hormone imbalances, etc.; - generic drugs (18.3%; Sandoz). Net sales are distributed geographically as follows: Europe (36.5%), the United States (34.9%), Asia/Africa/Australasia (20.9%), Canada and Latin America (7.7%).

Sector

Pharmaceuticals

Calendar

08:30am - R&D Day

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

NOVARTIS : Healthy Q3; guidance upgraded ‘again’

October 24, 2023 at 10:00 am EDT

Novartis AG : Sandoz takes its first steps on the stock exchange

October 04, 2023 at 10:32 am EDT

More Strategies

Ratings for Novartis AG

Trading Rating :

Investor Rating :

ESG Refinitiv :

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

97.56USD

Average target price

104.84USD

Spread / Average Target

+7.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi. (M$)
NOVARTIS AG	+2.18%	201 B $
ELI LILLY AND COMPANY	+62.37%	532 B $
NOVO NORDISK A/S	+47.10%	464 B $
JOHNSON & JOHNSON	-14.30%	364 B $
ABBVIE INC.	-13.84%	246 B $
ROCHE HOLDING AG	-18.80%	216 B $
ASTRAZENECA PLC	-11.56%	195 B $
PFIZER, INC.	-41.63%	170 B $
AMGEN INC.	+1.44%	141 B $
SANOFI	-4.20%	119 B $

Other Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 11:02:26 2023-11-28 am EST			5-day change	1st Jan Change
85.36 ^CHF	-0.72%		+0.40%	+2.18%

11:42am	European Midday Briefing : Stocks Struggle Again as November Rally Continues to Stall	DJ
10:13am	NOVARTIS AG : Gets a Neutral rating from UBS	ZD

European Midday Briefing : Stocks Struggle Again as November Rally Continues to Stall	05:42am	DJ
NOVARTIS AG : Gets a Neutral rating from UBS	04:13am	ZD
NOVARTIS : price target maintained by Oddo BHF	04:12am	CF
NOVARTIS AG : Jefferies reaffirms its Buy rating	04:03am	ZD
Novartis Touts R&D Pipeline Progress, Upgraded Midterm Targets as Pure-play Medicines Company	03:50am	MT
Novartis lifts sales growth target to 5% per year through 2027	02:28am	RE
Novartis Raises Mid-Term Sales Growth Targets	01:58am	DJ
Novartis Raises Mid-term Targets After Emerging as Pure-play Medicines Company	01:52am	MT
Novartis: medium-term growth target raised	01:48am	CF
Huluwa Pharma Registers Hypertension Drug	01:18am	MT
Novartis aims for 5% annual sales growth through 2027	01:05am	RE
Novartis Closes Sale of Cell, Gene Therapy Unit to Seqens	11:25pm	MT
Jefferies: Investor Interest Shifts from Daiichi Sankyo to Chugai and Otsuka Holdings	Nov. 27	MT
NOVARTIS AG : Receives a Buy rating from Deutsche Bank	Nov. 27	ZD
Novartis Recalls Two Lots of Sandimmune Cyclosporine Oral Solution Over Incorrect Dosing Concerns	Nov. 24	MT
US Jobless Data Sends Swiss Equities Higher Ahead of Thanksgiving Break	Nov. 22	MT
BeiGene to buy global rights to Ensem's experimental cancer therapy	Nov. 21	RE
Novartis: presents data from over 100 trials	Nov. 20	CF
Bayer stops blood thinner drug trial due to lack of effect, in major setback	Nov. 20	RE
Alcon slightly misses Q3 net sales, narrows full-year outlook	Nov. 15	RE
Genscript Subsidiary Legend Biotech Grants Novartis License to Develop Anti-Cancer Drug	Nov. 13	MT
Legend Biotech Gets $100 Million From Novartis in Global License Agreement for CAR-T Therapies	Nov. 13	MT
Transcript : Novartis AG - Special Call	Nov. 13	CI
Legend Biotech Subsidiary in License Agreement With Novartis	Nov. 13	DJ
Starpharma Names CEO	Nov. 09	MT